Authors: Jordan Francke, MD, MPH
IARS Daily Dose, May 3, 2026. “Is Universal Opioid-Free Anesthesia a Realistic Target? IARS Experts Debate This Timely Question.”
This article summarized a major debate session from the 2026 IARS and SOCCA Annual Meeting examining whether universal opioid-free anesthesia is a practical or evidence-based goal in perioperative medicine. The session highlighted the growing movement toward minimizing opioid exposure while also emphasizing the ongoing need for effective analgesia and the lack of definitive evidence supporting complete opioid elimination for all surgical patients.
The discussion opened with Dr. James Rathmell from Harvard Medical School and Editor-in-Chief of Anesthesiology. Dr. Rathmell noted that anesthesiology literature has seen a substantial increase in studies examining both opioid-free anesthesia and opioid-sparing techniques. He reviewed the historical role of opioids in perioperative care, including evidence dating back to the 1960s demonstrating that high-dose intravenous opioids could provide profound analgesia with relative hemodynamic stability, particularly in frail surgical patients. However, he emphasized that opioids also carry major consequences including respiratory depression, postoperative ileus, delirium, persistent opioid use, and opioid-induced hyperalgesia. Persistent postoperative opioid use occurs in approximately 5–10% of surgical patients and remains a major public health concern.
Dr. Rathmell discussed the important POFA (Postoperative and Opioid-free Anesthesia) trial, which attempted to evaluate opioid-free anesthesia strategies but was prematurely terminated because patients receiving high-dose dexmedetomidine developed significant bradycardia. He explained that many opioid-free anesthesia studies suffer from methodological weaknesses including small sample sizes, inconsistent anesthetic protocols, and reliance on surrogate outcomes rather than clinically meaningful endpoints. While he acknowledged that opioid-free anesthesia may have value in select populations such as patients with severe obstructive sleep apnea, opioid use disorder, or severe postoperative nausea and vomiting, he argued that the broader goal should not necessarily be total opioid elimination. Instead, he recommended “de-centering” opioids within the anesthetic plan while still using them judiciously when clinically beneficial.
Dr. Karim Ladha from the University of Toronto presented the counterargument in favor of broader opioid-free approaches. He questioned why anesthesiologists continue to rely so heavily on opioids despite their known adverse-effect profile. Dr. Ladha highlighted studies demonstrating successful opioid-free anesthetics in bariatric surgery, breast surgery, laparoscopic abdominal surgery, and ambulatory orthopedic procedures through the combined use of regional anesthesia and multimodal analgesia. He argued that the POFA trial may not accurately represent modern opioid-free anesthesia because it relied heavily on high-dose dexmedetomidine as a single substitute agent rather than balanced multimodal regimens employing several drugs with complementary mechanisms of action. Like Dr. Rathmell, he supported the idea of moving away from opioid-centered care. However, he emphasized that future studies should focus less on reductions in morphine-equivalent dosing and more on meaningful patient-centered outcomes such as pain control, recovery of function, postoperative opioid requirements, and patient satisfaction.
The final panelist, Dr. Cornelius Groenewald from Stanford University, argued strongly against complete opioid avoidance. He stated directly that he believes every patient should receive fentanyl before surgical incision. Dr. Groenewald reviewed evidence showing that 30–80% of patients experience moderate-to-severe acute postoperative pain and that poorly controlled acute pain is strongly associated with the development of chronic postoperative pain syndromes. He argued that for opioid-free anesthesia to truly replace opioid-based approaches, it must demonstrate not only fewer adverse effects but also superior analgesic efficacy. According to Dr. Groenewald, no randomized clinical trial has definitively shown opioid-free anesthesia to be both safer and more effective than traditional opioid-based anesthetic techniques. Although some studies have demonstrated reduced postoperative nausea or lower rates of remifentanil-associated hyperalgesia, the evidence remains insufficient to justify universal opioid elimination. He concluded that while regional anesthesia and multimodal analgesia are valuable and should be used whenever feasible, completely avoiding opioids may not be realistic or optimal for many surgical patients.
Overall, the debate reflected the evolving philosophy of perioperative pain management. Rather than framing opioids as universally harmful or universally necessary, the speakers largely agreed that the future likely lies in individualized opioid-sparing strategies that combine regional anesthesia, multimodal analgesia, and careful patient selection. The central disagreement was not whether opioid exposure should be minimized, but whether complete opioid elimination is achievable or even desirable across all surgical populations.
Key Points
• Opioid-free anesthesia remains controversial and lacks definitive evidence supporting universal adoption.
• The POFA trial was terminated early because of severe bradycardia associated with high-dose dexmedetomidine.
• Opioid-free anesthesia may be particularly beneficial in select patients such as those with obstructive sleep apnea, opioid use disorder, or severe PONV risk.
• Regional anesthesia and multimodal analgesia are central components of opioid-sparing strategies.
• Current evidence supports minimizing opioid exposure when possible, but not necessarily complete opioid elimination for every patient.
Thank you to IARS Daily Dose for allowing us to summarize and share this article.